XR Securities’s Inovio Pharmaceuticals INO Stock Holding History

XR Securities’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,348	Closed	-$70K	–	408
2022 Q2	$70K	Buy	+3,348	New	+$94.4K	0.02%	235

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

XR Securities's INO Position: Q3 2022 in Review

XR Securities sold out of Inovio Pharmaceuticals (INO) in Q3 2022, closing a stake of 3,348 shares — an estimated $70K sold.

XR Securities first reported a position in INO in Q2 2022 and held it in 1 quarter. The position peaked at $70K in Q2 2022. 182 funds tracked by Wall St. Rank hold INO as of Q3 2022.

XR Securities reported no remaining Inovio Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
XR Securities sold 3,348 Inovio Pharmaceuticals shares in Q3 2022, an estimated $70K.
XR Securities first reported a position in Inovio Pharmaceuticals in Q2 2022 and held it in 1 quarter.
XR Securities's Inovio Pharmaceuticals position peaked at $70K in Q2 2022.
182 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2022.

Based on XR Securities's 13F filing for Q3 2022, filed 18 Oct 2022.